Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis - No Study Results Posted - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

This study has been completed.

Study NCT00078338 Information provided by EMD Serono

First Received: February 23, 2004 Last Updated: April 19, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	September 2007
Estimated Primary Completion Date:	No date given

No publications provided by EMD Serono

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag BM; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 Oct;7(10):903-14. Epub 2008 Sep 11.

Back to top of Main Content